Protocol summary

Summary
The objective of this study was to assess the effect of subcutaneous Dexamethasone added to Bupivacaine on post cesarean pain control. 75 pregnant women were randomly assigned to receive following interventions at the time of skin closure, A) Bupivacaine 20 ml, 0.25% (SC) + Dexamethasone 4 ml (16 mg) (SC) + Normal saline 4 ml iv B) Bupivacaine 20 ml, 0.25%(SC) + Dexamethasone 4 ml (16 mg) IV + Normal saline 4 ml iv C) Bupivacaine 20 ml, 0.25% (SC) + normal saline 4 ml SC + normal saline 4 ml IV (placebo group). Pain intensity, systolic and diastolic blood pressure, heart rate and opioid consumption were evaluated at the recovery room, 6, 12, 24, 48 and 72 hours postoperatively.

General information

Acronym
IRCT registration information
IRCT registration number: IRCT138809242405N3
Registration date: 2010-01-20, 1388/10/30
Registration timing: retrospective

Last update:
Update count: 0
Registration date
2010-01-20, 1388/10/30
Registrant information
Name
Mitra Jabalameli
Name of organization / entity
Isfahan University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 31 1668 7472
Email address
jabalameli@med.mui.ac.ir
Recruitment status
Recruitment complete
Funding source
Isfahan University of Medical Sciences
Expected recruitment start date
2008-07-29, 1387/05/08
Expected recruitment end date
2009-10-10, 1388/07/18
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Evaluating the Effect of Subcutaneous Dexamethasone Added to Bupivacaine on Postcesarean Pain Relief
Public title
Evaluating the Effect of Subcutaneous Dexamethasone Added to Bupivacaine on Postcesarean Pain Relief
Purpose
Prevention
Inclusion/Exclusion criteria
Inclusion Criteria: Parturients, ASA physical status I-II, scheduled for elective cesarean section, under general anesthesia. Exclusion Criteria: patients with suspected or manifest bleeding disturbances, allergy to Bupivacaine or Dexamethasone, atopia, diabetes mellitus, the presence of liver or kidney diseases, abuse of drugs and patients with pregnant induced hypertension or preeclampsia.
Age
From 16 years old to 45 years old
Gender
Female
Phase
4
Groups that have been masked
No information
Sample size
Target sample size: 75
Randomization (investigator's opinion)
Randomized
Randomization description
Blinding (investigator's opinion)
Double blinded
Blinding description
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Isfahan University of Medical Sciences
Street address
Research Brueae, Isfahan University of Medical Sciences
City
Isfahan
Postal code
Approval date
2007-04-21, 1386/02/01
Ethics committee reference number
385552

Health conditions studied

1

Description of health condition studied
Complications of anaesthesia during pregnancy
ICD-10 code
O29.8
ICD-10 code description
Other complications of anaesthesia during pregnancy

Primary outcomes

1

Description
pain intensity
Timepoint
recovery room ,6 , 12, 24, 48 and 72 hours postoperative
Method of measurement
Visual Analogous Scale (VAS) and scoring from 0 to 10

Secondary outcomes

1

Description
Systolic blood pressure
Timepoint
at recovery room ,6 , 12, 24, 48 and 72 hours postoperative
Method of measurement
using mercury manometer

2

Description
Diastolic blood pressure
Timepoint
at recovery room ,6 , 12, 24, 48 and 72 hours postoperative
Method of measurement
using mercury manometer

3

Description
opioid consumption
Timepoint
at recovery room ,6 , 12, 24, 48 and 72 hours postoperative
Method of measurement
mili gram of opioid

4

Description
Heart rate
Timepoint
at recovery room ,6 , 12, 24, 48 and 72 hours postoperative
Method of measurement
Using EKG Monitoring

Intervention groups

1

Description
bupivacaine 20 ml,0.25% (SC) + dexamethasone 4 ml (16 mg) (SC) +Normal saline 4 ml iv, Duration of treatment: single dose .
Category
Treatment - Drugs

2

Description
bupivacaine 20 ml,0.25%(SC) + dexamethasone 4 ml (16 mg) iv+ Normal saline 4 ml iv, Duration of treatment: single dose .
Category
Treatment - Drugs

3

Description
bupivacaine 20 ml,0.25% (SC) + normal saline 4 ml SC+ normal saline 4 ml iv (placebo group). Duration of treatment: single dose .
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Alzahra General Hospital
Full name of responsible person
Dr. Mitra Jabalameli
Street address
Department of Anesthesia and intensive care, Alzahra General Hospital, sofe Boulevard
City
Isfahan

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Isfahan University of Medical Sciences
Full name of responsible person
Ms. Leila Bakhshi
Street address
Research Brueae, Medical School, Isfahan University of Medical Sciences
City
Isfahan
Grant name
385552
Grant code / Reference number
385552
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Isfahan University of Medical Sciences
Proportion provided by this source
100
Public or private sector
empty
Domestic or foreign origin
empty
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
empty

Person responsible for general inquiries

Contact
Name of organization / entity
Research Brueae, Medical School, Isfahan University of Medical Sciences
Full name of responsible person
Ms. Leila Bakhshi
Position
Research BS
Other areas of specialty/work
Street address
Research Brueae, Medical School, Hezar Jarib St. , Isfahan University of Medical Sciences
City
Isfahan
Postal code
Phone
+98 31 1792 2269
Fax
+98 31 1627 3397
Email
jabalameli@med.mui.ac.ir
Web page address
www.mui.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Isfahan University of Medical Sciences
Full name of responsible person
Dr. Mitra Jabalameli
Position
Specialist and Associate professor
Other areas of specialty/work
Street address
Department of Anesthesia and intensive care, Alzahra General Hospital, sofe Boulevard
City
Isfahan
Postal code
Phone
+98 31 1625 5555
Fax
+98 31 1627 3397
Email
jabalameli@med.mui.ac.ir
Web page address
www.mui.ac.ir

Person responsible for updating data

Contact

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty
Study Protocol
empty
Statistical Analysis Plan
empty
Informed Consent Form
empty
Clinical Study Report
empty
Analytic Code
empty
Data Dictionary
empty
Loading...